Enochian BioSciences

OverviewSuggest Edit

Enochian BioSciences (formerly known as DanDrit Biotech USA) is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer. Dendritic cells are critical components of the immune system. The ability of dendritic cells to induce a strong immune response is the basis of the vaccine therapies under development at DanDrit. The Company's expertise in producing dendritic cells from a patient’s blood is combined with conventional production methods to make new and advanced vaccines for cancer patients.

TypePublic
Founded2001
Websiteenochianbio.com

Latest Updates

Employees (est.) (Jun 2019)8(+100%)
Revenue (FY, 2016)$42.8 K
Share Price (Feb 2021)$3.7
Cybersecurity ratingAMore

Key People/Management at Enochian BioSciences

Mark Dybul

Mark Dybul

Executive Vice Chairman
Luisa Puche

Luisa Puche

Chief Financial Officer
Evelyn D'An

Evelyn D'An

Independent Director
Tung Nguyen

Tung Nguyen

Director of Molecular Biology
Gregg H. Alton

Gregg H. Alton

Independent Director
Carol L. Brosgart

Carol L. Brosgart

Independent Director
Show more

Enochian BioSciences Office Locations

Enochian BioSciences has an office in Los Angeles
Los Angeles, CA, US
2080 Century Park E
Show all (1)

Enochian BioSciences Financials and Metrics

Enochian BioSciences Revenue

Enochian BioSciences's revenue was reported to be $42.77 k in FY, 2016
USD

Net income (Q3, 2020)

(1.5m)

EBIT (Q3, 2020)

(3.8m)

Market capitalization (5-Feb-2021)

172.5m

Closing stock price (5-Feb-2021)

3.7

Cash (31-Mar-2020)

10.9m

EV

169.1m
Enochian BioSciences's current market capitalization is $172.5 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

42.8k

Cost of goods sold

295.7k65.9k5.3k

Gross profit

(295.7k)37.5k

Gross profit Margin, %

88%
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

42.5k

Cost of goods sold

17.7k64.3k143.5k44.6k5.2k

Gross profit

37.3k

Gross profit Margin, %

88%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

336.06.7k3.0m421.1k23.4k3.9m15.6m12.3m

Accounts Receivable

8.0k432.1k695.4k223.8k122.9k20.8k

Prepaid Expenses

13.7k33.4k38.3k192.0k

Current Assets

13.6k20.0k5.0m1.9m732.5k4.2m15.8m12.5m
USDQ2, 2012

Financial Leverage

10 x
Show all financial metrics

Enochian BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Enochian BioSciences Online and Social Media Presence

Embed Graph

Enochian BioSciences News and Updates

Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B a…

Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

Company encouraged by strong alignment with views of FDA’s CBER regarding ENOB-HV-01LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the c…

Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV

LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA has scheduled an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeti…

Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure

LOS ANGELES, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Institute.

Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the appointment of two board members:

- Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; - Carol Brosgart, MD, Clinical Professor of Medicine at the University of California, San Francisco (UCSF), former senior advisor on hepatitis for the Centers for…

Enochian BioSciences Blogs

Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) — Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conf…

Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis B LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE)–(NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announ…

Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures

• First presentation of a novel approach to potentially cure HIV – An in vivo study demonstrated a 167 percent increase in engraftment of genetically modified cells Poster Presentation Link Here Slide Presentation Link Here The post Enochian Biosciences Announces Three Scientific Presentations on Po…

Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting

• Three of three abstracts were accepted for presentation at the Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT); • The presentations advance the scientific foundation of Enochian’s broad and deep pipeline for potential cures for HIV and Hepatitis B Virus (HBV) infection LOS …

Enochian Biosciences, A Company Focused on Gene-Modified Cellular Therapy in Infectious Disease and Cancer, Announces the Appointment of Two Board Members

• Gregg Alton, the former interim CEO of Gilead Sciences, a company he served in many key roles during his more than 20 year tenure, and; • Carol Brosgart, MD, Clinical Professor of Medicine at the University of California, San Francisco (UCSF), former senior advisor on hepatitis for the Centers for…

Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus

LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) — Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B. Hepatitis B virus (HBV) can …
Show more

Enochian BioSciences Frequently Asked Questions

  • When was Enochian BioSciences founded?

    Enochian BioSciences was founded in 2001.

  • Who are Enochian BioSciences key executives?

    Enochian BioSciences's key executives are Mark Dybul, Luisa Puche and Evelyn D'An.

  • How many employees does Enochian BioSciences have?

    Enochian BioSciences has 8 employees.

  • Who are Enochian BioSciences competitors?

    Competitors of Enochian BioSciences include Celltrion Healthcare, Myrexis and Carna Biosciences.

  • Where are Enochian BioSciences offices?

    Enochian BioSciences has an office in Los Angeles.

  • How many offices does Enochian BioSciences have?

    Enochian BioSciences has 1 office.